Abstract:
Replacing the functionality of an active digital loop carrier subsystem (DLCSS) or active module with a standby DLCSS or standby module in an IP addressable telecommunication switch is effected by providing only a single externally-known IP address for the module pair and then swapping the IP address of the active module for the IP address of the standby module so that externally-connected devices recognize only the IP address for the module in use. A central network management station in communication with a local nonvolatile memory element controls the IP address swapping.
Abstract:
Method for the prevention or treatment of pruritus with anti-pruritic compounds is provided. The compounds of formulae I, II, IIA, III, IIIA, IV and IVA have the structure: wherein R1, R2, R3, R4; and X, X4, X5, X7, X9; Y, Z and n are as described in the specification.
Abstract:
Anti-pruritic pharmaceutical formulations containing kappa agonist compounds and methods of prevention or treatment of pruritus in a mammal with the anti-pruritic formulations.
Abstract:
Compounds having kappa opioid agonist activity, compositions containing them and method of using them as analgesics and anti-pruritic agents are provided.The compounds of formula III having the structure: ##STR1## wherein Ar and X.sup.7 ;R.sub.1 and R.sub.2 ; andn are as described in the specification.
Abstract:
Compounds having kappa opioid agonist activity, compositions containing them and method of using them as analgesics are provided. The compound of formulae IV having the structure: ##STR1## wherein X.sub.9 ;R.sub.1, R.sub.2, R.sub.3, R.sub.4 ;and n are as described in the specification.
Abstract:
Anti-pruritic pharmaceutical formulations containing kappa agonist compounds and methods of prevention or treatment of pruritus in a mammal with the anti-pruritic formulations.
Abstract:
Compounds, compositions and method of treating hyperalgesia comprising a compound of formula I, II, III and IV as defined in the specification.
Abstract:
Substituted N-arylmethyl and heterocyclylmethyl-1H-pyrazolo[3,4-b]quinolin-4-amines, pharmaceutical compositions containing them and methods for a) effecting c-GMP-phosphodiesterase inhibition, b) treating heart failure and/or hypertension, c) reversing or reducing nitrate-induced tolerance and d) treating angina pectoris, congestive heart disease and myocardial infarction utilizing them.
Abstract:
4-R.sup.4 -R.sup.5 -2-Saccharinylmethyl aryl carboxylates, useful in the treatment of degenerative diseases, are prepared by reacting a 4-R.sup.4 -R.sup.5 -2-halomethylsaccharin with an arylcarboxylic acid in the presence of an acid-acceptor.
Abstract:
Substitutued heterocyclylisoquinolinium salts, pharmaceutical compositions containing them and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.